- Home
- REVBW vs HIMX Comparison
REVBW vs HIMX Comparison
Compare REVBW & HIMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- HIMX
- Stock Information
- Founded
- REVBW N/A
- HIMX 2001
- Country
- REVBW United States
- HIMX Taiwan
- Employees
- REVBW 9
- HIMX N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- HIMX Semiconductors
- Sector
- REVBW Health Care
- HIMX Technology
- Exchange
- REVBW Nasdaq
- HIMX Nasdaq
- Market Cap
- REVBW N/A
- HIMX N/A
- IPO Year
- REVBW 2020
- HIMX 2006
- Fundamental
- Price
- REVBW $0.01
- HIMX $8.85
- Analyst Decision
- REVBW
- HIMX Buy
- Analyst Count
- REVBW 0
- HIMX 1
- Target Price
- REVBW N/A
- HIMX $15.00
- AVG Volume (30 Days)
- REVBW N/A
- HIMX 1.9M
- Earning Date
- REVBW N/A
- HIMX 02-13-2025
- Dividend Yield
- REVBW N/A
- HIMX 3.30%
- EPS Growth
- REVBW N/A
- HIMX 10.98
- EPS
- REVBW N/A
- HIMX 0.44
- Revenue
- REVBW N/A
- HIMX $897,257,000.00
- Revenue This Year
- REVBW N/A
- HIMX $12.75
- Revenue Next Year
- REVBW N/A
- HIMX N/A
- P/E Ratio
- REVBW N/A
- HIMX $19.93
- Revenue Growth
- REVBW N/A
- HIMX N/A
- 52 Week Low
- REVBW N/A
- HIMX $4.80
- 52 Week High
- REVBW N/A
- HIMX $9.80
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- HIMX 63.94
- Support Level
- REVBW N/A
- HIMX $7.09
- Resistance Level
- REVBW N/A
- HIMX $8.62
- Average True Range (ATR)
- REVBW 0.00
- HIMX 0.49
- MACD
- REVBW 0.00
- HIMX 0.01
- Stochastic Oscillator
- REVBW 0.00
- HIMX 86.70
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).